Ansa Biotechnologies Raises $71.5M to Expand DNA Synthesis
Ansa Biotechnologies Raises $71.5M in Series C Funding Ansa Biotechnologies has raised $71.5 million in an oversubscribed Series C financing. Ansa has raised the total funding to date to $211 The post Ansa Biotechnologies Raises $71.5M to Expand DNA Synthesis appeared first on Ventureburn .
Ansa Biotechnologies secured $71.5 million in Series C funding to bolster its DNA synthesis capabilities. The financing brings the company's total capital raised to $211 million. New investors Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital joined existing backers Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures.
The funding, which was oversubscribed, will enable Ansa to expand its manufacturing operations and team. The company's enzymatic DNA synthesis technology allows for the production of complex DNA sequences that are difficult to create using traditional methods. Ansa's products are utilized across various research fields, including vaccines, agrigenomics, cell and gene therapies, and drug discovery.
The company aims to meet growing demand from researchers looking for more ambitious DNA constructs to carry out AI-driven drug discovery. Reliable manufacturing is crucial for scientists to plan and execute their experiments efficiently. Ansa offers a Shipping Guarantee to ensure customers receive their orders by the target date.
With a new board of directors comprising experienced leaders from biotechnology, life sciences, and venture capital, Ansa is well-positioned to drive further advancements in DNA synthesis and support complex biological research.
Written by urgent.news from Ventureburn's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.